Boehringer Ingelheim International Gmbh

Aeterna Zentaris Gmbh

Centre National De La Recherche Scientifique

University of Montpellier I

University of Montpellier Ii

Æterna Zentaris Gmbh

Babette Aicher

Thomas Stephen Coulter

Stefan Jaekel

Tanja Reuter

Stephen Murfin

Steven Taylor

Matthias Gerlach

Eckhard Günther

Jean Martinez

Michael Teifel

Jürgen Engel

Klaus Paulini

Peter Schmidt

Jean-Alain Fehrentz

Herbert Sindermann

Gilbert Mueller

Lars Blumenstein

Anne-Laure Blayo

Arndt-René Kelter

Valery Thammalaksa

Gilbert MÜLLER

The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions

The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder, drug abuse, growth retardation, cachexia, short-, medium-, and/or long term regulation of energy balance, short-, medium-, and/or long term regulation (stimulation and/or inhibition) of food intake, intake of rewarding food, adipogenesis, adiposity and/or obesity, body weight gain and/or reduction, diabetes, diabetes type I, diabetes type II, tumor cell proliferation, inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors

The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II.  A particularly effective treatment includes administering a combination of perifosine and capecitabine.

Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals

The present invention relates to the use of pyrazolopyrimidine compounds for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2or Mnk2) and/or variants thereof.

Mnk1 or Mnk2 inhibitors

Growing community of inventors

Frankfurt am Main, Germany

Babette Aicher